Welcome to our dedicated page for Outset Medical news (Ticker: OM), a resource for investors and traders seeking the latest updates and insights on Outset Medical stock.
Outset Medical, Inc. (symbol: OM) is a pioneering medical technology company committed to revolutionizing the dialysis experience. The company’s primary product, Tablo, is an innovative dialysis machine designed to simplify and streamline the process of Renal Replacement Therapy. By focusing on a patient-centric approach, Outset Medical places patient care, ease of use, and cost-efficiency at the forefront of its operations.
The Tablo dialysis system is built with a user-friendly touchscreen display that offers step-by-step visual and conversational instructions, making it accessible to both patients and caregivers, regardless of their experience level. This intuitive design dramatically reduces the complexity and cost associated with traditional dialysis treatments. Tablo can be used across various settings, including hospitals, chronic care dialysis clinics, and at home, making it a versatile solution for renal care.
Outset Medical’s mission is to improve the care experience for patients, families, providers, and physicians, while also enhancing cost-efficiencies for healthcare providers. The company achieves this by combining expertise from different healthcare fields, fostering an environment of cross-disciplinary innovation. This approach has led to significant advancements in dialysis technology and patient care.
Recent achievements include regulatory approvals and partnerships aimed at expanding Tablo’s reach and improving its functionalities. Financially, Outset Medical has shown robust growth, supported by a dedicated team of professionals and continuous innovation in their product offerings. The company's efforts are geared towards giving people their time back by reducing the dialysis process's complexity and duration.
Stay updated with the latest developments and news about Outset Medical, Inc. to learn how this industry leader is transforming renal care.
Outset Medical, Inc. (Nasdaq: OM) will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 11, 2021, at 11:45am PT / 2:45pm ET. The event aims to discuss the company’s innovative dialysis technology, the Tablo Hemodialysis System, which simplifies dialysis treatment and enhances patient experience. A live and archived webcast will be available on Outset's website. This system allows for greater accessibility and efficiency in dialysis care, operating from hospital to home.
Outset Medical, Inc. (Nasdaq: OM) will announce its Q1 2021 financial results on May 5, 2021, after market close. A conference call with CEO Leslie Trigg and CFO Rebecca Chambers is scheduled for the same day at 2:00 PM PT (5:00 PM ET) to discuss these results. Outset is known for its innovative Tablo Hemodialysis System, designed to simplify dialysis treatment and reduce costs, allowing for flexibility in care delivery from hospitals to home settings.
Outset Medical, Inc. (Nasdaq: OM) announced the completion of its public offering, selling 2,945,864 shares at $53.50 each, alongside 3,890,723 shares from certain stockholders. The offering included 891,728 additional shares due to underwriter options, yielding net proceeds of approximately $149.7 million for Outset, after costs. The offering was managed by Morgan Stanley, BofA Securities, and Goldman Sachs, among others. Outset aims to leverage these funds for advancing its Tablo Hemodialysis System, which simplifies dialysis for patients and providers.
Outset Medical's Tablo Hemodialysis System has been awarded as one of seven winners in Round 2 of the KidneyX COVID-19 Kidney Care Challenge by the U.S. Department of Health and Human Services and the American Society of Nephrology. This recognition highlights Tablo's innovative solution for dialysis amid the pandemic, aimed at reducing transmission risks of COVID-19. With features like remote monitoring through TabloHub, Tablo simplifies dialysis, enhances patient care, and allows flexibility in resource management. The KidneyX Challenge has a total prize pool of $300,000 for innovative kidney care solutions.
Outset Medical, Inc. (Nasdaq: OM) has announced the pricing of a public offering of 2,500,000 shares of its common stock at $53.50 per share, alongside 3,444,859 shares sold by existing stockholders. Additionally, underwriters have a 30-day option to purchase up to 891,728 shares. The offering is set to close on April 13, 2021, subject to customary conditions. Morgan Stanley, BofA Securities, and Goldman Sachs are leading the underwriting effort. A registration statement related to this offering is effective with the SEC.
Outset Medical, Inc. (Nasdaq: OM) announced a proposed underwritten public offering of 2,500,000 shares of common stock, with an additional 750,000 shares option for underwriters. This offering is under market conditions and is subject to SEC registration. Morgan Stanley, BofA Securities, and Goldman Sachs are the lead managers for the offering. The funds raised are aimed at reducing dialysis costs and complexity through their innovative Tablo Hemodialysis System. However, completion of the offering is uncertain, depending on market conditions and other factors.
Outset Medical, Inc. (Nasdaq: OM) has appointed Andrea Saia to its board of directors, aiming to enhance its consumer focus and expand the home dialysis market. Saia, a global business leader with 40 years of experience, previously worked with major brands like Novartis and Procter & Gamble. CEO Leslie Trigg emphasized her expertise in the consumer health landscape as vital for Outset's growth. The company also announced that Ali Osman has stepped down from the board after contributing to its recent growth.
Outset Medical, Inc. (Nasdaq: OM) reported significant financial growth for the fourth quarter and full year ended December 31, 2020. Fourth-quarter revenue reached $17.2 million, a 143% increase year-over-year, while full-year revenue was $49.9 million, a 231% increase. Despite this growth, the company incurred a net loss of ($32.0) million in Q4 and ($79.3) million for the full year. Outset projects 2021 revenue between $89 million and $94 million, indicating a strong outlook with 78% to 88% anticipated growth over 2020.
Outset Medical, Inc. (Nasdaq: OM) will release its financial results for Q4 and the full year of 2020 on March 9, 2021, after market close. A conference call led by CEO Leslie Trigg and CFO Rebecca Chambers will discuss financial and operating results at 2:00 PM PT (5:00 PM ET). Investors can participate via phone or listen to a live and archived webcast on Outset's website. Outset is recognized for its Tablo Hemodialysis System, designed to streamline dialysis care and facilitate treatment at home or in clinics.
Outset Medical, Inc. (Nasdaq: OM) has appointed Karen Drexler to its board of directors, enhancing its leadership in the medtech field. Drexler, recognized as a top corporate director by Women Inc. magazine, brings valuable experience from notable companies like ResMed and Sandstone Diagnostics. Her expertise in data analytics and consumer-centric approaches aligns with Outset's strategies for its Tablo System, aimed at improving patient experiences in dialysis. Additionally, TJ Carella has stepped down from the board after a decade of impactful contributions.
FAQ
What is the current stock price of Outset Medical (OM)?
What is the market cap of Outset Medical (OM)?
What is Outset Medical, Inc.?
What product does Outset Medical offer?
How does the Tablo dialysis system work?
In what settings can Tablo be used?
What is the company's main mission?
Who can use the Tablo machine?
What is unique about the Tablo machine?
How does Outset Medical foster innovation?
What recent achievements does Outset Medical have?